VALN - Valneva updates 2023 guidance sees PRV sale in early 2024
2023-12-29 17:38:59 ET
More on Valneva
- Valneva: Q3 Earnings, Vaccine Valiance, Outshining Moderna
- Valneva SE (VALN) Q3 2023 Earnings Call Transcript
- Valneva's Vaccination Valor: A Buy Rating Justified
- Pfizer, Valneva complete recruitment for Phase 3 Lyme vaccine study
- Valneva chikungunya vaccine to go through accelerated review in Europe
For further details see:
Valneva updates 2023 guidance, sees PRV sale in early 2024